Hanall Biopharma's 'BioTop' Ranks No.1 in External Prescriptions for Dermatological Agents in Q1

21 Billion KRW Prescriptions in Q1

BioTopD (Photo by HanAll Biopharma)

[Asia Economy Reporter Kim Ji-hee] HanAll Biopharma announced on the 7th that its probiotic pharmaceutical 'BioTop' ranked first in off-prescription sales in the antidiarrheal (A7F microbial antidiarrheal) category in the first quarter of this year.

According to HanAll Biopharma, based on data compiled by the market research firm Ubist, BioTop was prescribed 2.1 billion KRW in the first quarter of this year. Among about 100 products in the antidiarrheal category, it was the pharmaceutical most prescribed by doctors. Since its launch in 2016, BioTop's sales have rapidly increased with an average annual growth rate of 129% over four years.

BioTop is used to alleviate symptoms such as diarrhea, constipation, loose stools, and abdominal bloating. Unlike health functional foods, it is a pharmaceutical officially approved by the Ministry of Food and Drug Safety for the direct treatment or prevention of diseases. Along with lactic acid bacteria widely used in probiotic products, it contains 'naksan bacteria' that suppress harmful intestinal bacteria and 'danghwa bacteria' that promote the growth of beneficial bacteria.

A HanAll Biopharma official stated, "The three beneficial bacteria combined in BioTop have a symbiotic effect, increasing intestinal beneficial bacteria more than when taken individually," and added, "Naksan bacteria, which has recently attracted attention in the medical community, is included in high concentrations, leading to expanded prescriptions in clinics and general hospitals."

This content was produced with the assistance of AI translation services.